QS Research · Michael Burry's Scion Capital analyst template · 2006
TELUS CORP (TU)
As of 2026-11-20 · 10/15 boxes filled from SEC filings and market data
Report price $11.07 (close 2026-11-20)
Conclusion: WATCH
Conviction low · base case -58% · downside -70% · upside +10%
The market is paying 22.1x FY Dec 2025 net income of C$1.11B and 7.8x EV/EBITDA, a price that embeds +7.1% revenue growth a year for 10 years against +0.6% delivered in the fiscal year to 2025-12-31. The call is WATCH with low conviction, because the key numbers run only to 2025-12-31 and newer quarterly results exist. The base case is -57.5% at $4.71, a P/E of 9.4x, the peer median P/E. The downside is -70.2% at $3.30, the base case's multiple on -30.0% earnings. The upside is +10.0% at $12.18, +10% earnings at today's P/E of 22.1x. The three cases lean one way, but evidence that stops at the fiscal year-end, plus the unsolicited Québecor proposal and its unresolved regulatory questions, leaves the range open enough that low conviction is the honest setting and no stronger label is warranted.
Key numbers
- Share price: $11.07
- Market cap: $17.14B
- Latest financial period: FY Dec 2025 to Dec 31, 2025
- Revenue (FY Dec 2025): C$20.51B
- EV / EBITDA (FY Dec 2025): 7.8x
- P/E (FY Dec 2025): 22.1x
- FCF yield: 8.7%
- Price / book: 1.56x
- EV / FCF (FY Dec 2025): 23.5x
- Revenue growth (latest fiscal year): +0.6%
- ROIC (FY Dec 2025): 3.4%
- WACC: 4.2%
- Economic profit spread: -0.7 pts
The 15 boxes
- ✓ 1. Long-form business notes
TELUS CORP — which filed as TELUS CORPORATION until 2001-01-18 — is a Canadian communications company reporting TELUS technology solutions (mobile network, fixed data, health), TELUS Health and TELUS Digital; it files a 40-F, and all figures here are in CAD. FY2025 (year ended Dec 31, 2025) revenue was C$20.51B with operating income C$2.36B, net income C$1.11B and operating cash flow C$4.87B against capex C$2.73B. Revenue rose every year in the six-year window (C$15.46B in FY2020), but operating income did not follow — C$3.07B in FY2021 versus C$2.36B in FY2025 — as D&A rose from C$3.22B to C$4.06B. Between the oldest and newest annual periods the business was reshaped by acquisition and build: LifeWorks (Sept 1, 2022), WillowTree (Jan 3, 2023), Proagrica and Vumetric (2024), a 5G/fibre footprint of about 32.3M Canadians covered and more than 3.4M premises passed at Dec 31, 2024, and 3800 MHz spectrum bought in Nov 2023.
- ✓ 2. Competitive advantage
The sources only let me measure the moat indirectly: revenue grew 32.7% from FY2020 (C$15.46B) to FY2025 (C$20.51B) but operating income fell from C$2.48B to C$2.36B and operating margin slid from 16.0% to 11.5% (both computed from the XBRL facts), so scale has not converted into pricing power or operating leverage in that window. Returns on equity were 7.0% in FY2025 versus 10.0% in FY2020 (computed on total equity), and the growth was funded with heavy capital spending (D&A C$4.06B on C$20.51B of FY2025 revenue, capex C$2.73B) plus a 20.1% increase in diluted shares from FY2020 to FY2025. The only real barriers visible in these sources are capital intensity and the regulatory/competitive disclosure the 40-F points to; it names no competitors and gives no subscriber, churn or licence detail here.
- ✓ 3. 10-Q takeaways
Q3 2026 (three months ended September 30, 2026) operating revenues were $5,020M, down 1% from $5,067M, with service revenue $4,481M and equipment revenue $539M. The quarter swung to a $660M net loss and $0.42 basic loss per share after an $800M non-cash TELUS Health goodwill impairment; adjusted net income was $251M (-32%) and adjusted EBITDA $1,760M (-5%). Free cash flow fell 35% to $396M as capex rose 8%, cash was $1,308M at September 30, 2026 versus $2,621M at December 31, 2025, and net debt/EBITDA was 3.6x. The release reaffirmed full-year 2026 guidance and gave multi-year targets of about $900M annualized cash savings exiting 2028 and 3.0x or lower leverage by year-end 2028.
- ○ 4. Corporate governance
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ○ 9. Insider trading interpretation
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.